Projected $325 Million Revenue for Can-Fite from Piclidenoson Veterinary Approval.

Can-Fite BioPharma, a biotechnology company based in Israel, has recently announced exciting projections for their drug Piclidenoson in the veterinary market. The company expects to receive $325 million in upfront payments and royalties on sales upon regulatory approval for veterinary use. This substantial sum is projected to be accumulated over the next decade, assuming a launch date in 2029. This news marks a significant milestone for Can-Fite as they expand their reach into the veterinary sector with their innovative drug.

Piclidenoson, the drug in question, is a novel A3 adenosine receptor agonist that has shown promising results in preclinical studies for various indications. The drug’s potential in the veterinary market has sparked interest and optimism among investors and stakeholders. Can-Fite’s focus on developing new treatment options for both human and animal health underscores their commitment to advancing healthcare through cutting-edge research and development.

The projected $325 million in upfront payments and royalties on sales reflects the confidence in Piclidenoson’s efficacy and market potential. This financial forecast highlights the significant impact that the drug could have on Can-Fite’s revenue stream and overall growth trajectory. With the veterinary market presenting a lucrative opportunity for the company, Can-Fite is poised to capitalize on this potential windfall in the coming years.

The regulatory approval process for Piclidenoson in the veterinary market will be a crucial step in realizing the projected $325 million in upfront payments and royalties. Can-Fite’s strategic approach to securing approval and commercializing the drug will be key to achieving success in this endeavor. The company’s track record of innovation and dedication to scientific excellence bodes well for the future prospects of Piclidenoson in the veterinary sector.

Overall, Can-Fite’s optimistic projections for Piclidenoson in the veterinary market signal a promising future for the company and its innovative drug pipeline. The projected $325 million in upfront payments and royalties on sales underscore the potential impact of Piclidenoson in improving animal health outcomes. As Can-Fite continues to advance its research and development efforts, the company’s commitment to innovation and growth remains steadfast, positioning them as a key player in the biotechnology industry.

AI-generated summary. Full credits:

Source: GlobeNewswire.
Author: Can-Fite BioPharma Ltd..
Date: 2025-03-20T13:45:00Z.
Read more: https://www.globenewswire.com/news-release/2025/03/20/3046342/0/en/Can-Fite-Partner-Vetbiolix-Accelerate-Piclidenoson-Development-with-Advanced-Clinical-Trial-for-Canine-Osteoarthritis-in-a-3-8-Billion-Market.html.